Products Ramucirumab
Ramucirumab Phase 1 Completed 💤 Quiet Interest: 29/100
Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
Dec 11, 2015 → Jul 16, 2019
About Ramucirumab Ramucirumab is a phase 1 stage product being developed by Eli Lilly for Pediatric Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT02564198. Target conditions include Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor.
What happened to similar drugs? 3 of 19 similar drugs in Pediatric Solid Tumor were approved
Clinical Trials (9) NCT ID Phase Status Start Completion Indication NCT02065765 Pre-clinical Completed — — Metastatic Gastric Cancer NCT04557384 Phase 1 Terminated Feb 23, 2021 May 25, 2021 Advanced Solid Tumor NCT03745430 Phase 1/2 Completed Jan 29, 2019 Apr 23, 2023 Pancreatic Adenocarcinoma NCT02564198 Phase 1 Completed Dec 11, 2015 Jul 16, 2019 Pediatric Solid Tumor NCT02443883 Phase 2 Completed Jul 7, 2015 Jun 5, 2019 Gastric Adenocarcinoma NCT01983878 Phase 2 Completed Dec 1, 2013 Feb 1, 2016 Gastric Cancer NCT01682135 Phase 1 Completed Nov 1, 2012 Mar 1, 2015 Solid Tumor NCT00721162 Phase 2 Completed Aug 1, 2008 Aug 1, 2015 Ovarian Cancer NCT00515697 Phase 2 Completed Nov 1, 2007 May 1, 2011 Metastatic Renal Cell Carcinoma
Product Company Stage Hype Score erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3